Stock INAF PT INDOFARMA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Indofarma Tbk

Equities

INAF

ID1000068406

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 06:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
191 IDR +8.52% Intraday chart for PT Indofarma Tbk +28.19% -67.07%
2023 PT Indofarma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 PT Indofarma Tbk Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 18,285,678 20,145,239 2,696,363 12,490,048 6,911,367 3,564,158
Enterprise Value (EV) 1 18,597,627 20,574,256 3,028,290 12,789,362 7,135,390 3,921,619
P/E ratio -395 x -616 x 339 x 403,000 x -184 x -8.32 x
Yield - - - - - -
Capitalization / Revenue 11.2 x 12.6 x 1.98 x 7.28 x 2.38 x 3.12 x
EV / Revenue 11.4 x 12.9 x 2.23 x 7.45 x 2.46 x 3.43 x
EV / EBITDA 619 x 1,775 x 72.8 x 167 x 91.8 x -8.68 x
EV / FCF 271 x -122 x 42.5 x 87.1 x 115 x 46.3 x
FCF Yield 0.37% -0.82% 2.35% 1.15% 0.87% 2.16%
Price to Book 34.7 x 40.6 x 5.34 x 29 x 13.6 x 41.3 x
Nbr of stocks (in thousands) 3,099,268 3,099,268 3,099,268 3,099,268 3,099,268 3,099,268
Reference price 2 5,900 6,500 870.0 4,030 2,230 1,150
Announcement Date 7/20/18 4/1/19 7/2/20 4/26/21 4/20/22 3/31/23
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 1,631,317 1,592,980 1,359,175 1,715,588 2,901,987 1,144,108
EBITDA 1 30,043 11,588 41,583 76,781 77,718 -451,762
EBIT 1 -5,359 -21,590 22,746 53,215 53,093 -470,622
Operating Margin -0.33% -1.36% 1.67% 3.1% 1.83% -41.13%
Earnings before Tax (EBT) 1 -56,817 -25,298 9,746 18,082 8,773 -517,558
Net income 1 -46,283 -32,736 7,961 27.58 -37,581 -428,463
Net margin -2.84% -2.06% 0.59% 0% -1.29% -37.45%
EPS 2 -14.93 -10.56 2.570 0.0100 -12.12 -138.2
Free Cash Flow 1 68,503 -169,274 71,245 146,883 61,826 84,650
FCF margin 4.2% -10.63% 5.24% 8.56% 2.13% 7.4%
FCF Conversion (EBITDA) 228.02% - 171.33% 191.3% 79.55% -
FCF Conversion (Net income) - - 894.93% 532,553.99% - -
Dividend per Share - - - - - -
Announcement Date 7/20/18 4/1/19 7/2/20 4/26/21 4/20/22 3/31/23
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 311,949 429,017 331,928 299,314 224,024 357,462
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 10.38 x 37.02 x 7.982 x 3.898 x 2.883 x -0.7913 x
Free Cash Flow 1 68,503 -169,274 71,245 146,883 61,826 84,650
ROE (net income / shareholders' equity) -8.4% -6.4% 1.59% 0.01% -8.01% -144%
ROA (Net income/ Total Assets) -0.23% -0.91% 1.01% 2.15% 1.78% -16.6%
Assets 1 20,123,017 3,605,673 791,427 1,284 -2,109,494 2,582,596
Book Value Per Share 2 170.0 160.0 163.0 139.0 164.0 27.90
Cash Flow per Share 2 58.90 41.70 48.80 51.00 123.0 87.00
Capex 1 78,085 29,344 2,597 10,897 21,270 12,468
Capex / Sales 4.79% 1.84% 0.19% 0.64% 0.73% 1.09%
Announcement Date 7/20/18 4/1/19 7/2/20 4/26/21 4/20/22 3/31/23
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT INDOFARMA TBK Stock PT Indofarma Tbk
-67.07% 36.78M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.51% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.09% 239B
NOVARTIS AG Stock Novartis AG
+10.17% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-7.03% 200B
AMGEN INC. Stock Amgen Inc.
+8.12% 167B
PFIZER, INC. Stock Pfizer, Inc.
-1.42% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INAF Stock
  4. Financials PT Indofarma Tbk
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW